Consensus Alvotech

Equities

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
13.37 ^USD	-1.69%		-7.15%	+16.46%

Apr. 30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
Apr. 30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

d1e35d5e47f.Ku2kIFL0iG55eBJRbUVlLLfYnhPyJuN9q52ttfLxWeY.YrrGS2CruycNEUYZAggiH_Ht21e5dbpQme_h07iIPIpE1ddUG6zSDA47YQ~a33bf67da57d0ada53a3228f91aa68e8

Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	Mar. 22	MT
Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	Jan. 29	MT
Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	23-10-20	MT
Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	23-09-21	MT
Deutsche Bank Adjusts Alvotech Price Target to $8 From $12, Maintains Hold Rating	23-06-30	MT
Deutsche Bank Adjusts Alvotech's Price Target to $12 From $8, Maintains Hold Rating	23-03-07	MT
Morgan Stanley Starts Alvotech at Equalweight With $10 Price Target	22-09-07	MT
Citigroup Double Downgrades Alvotech to Sell From Buy, Adjusts Price Target to $5 From $12	22-09-06	MT
Citigroup Starts Alvotech at Buy With $12 Price Target	22-07-26	MT
Deutsche Bank Initiates Coverage on Alvotech With Hold Rating, $10 Price Target	22-07-01	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.37 USD

Average target price

16.5 USD

Spread / Average Target

+23.41%

High Price Target

28 USD

Spread / Highest target

+109.42%

Low Price Target

6 USD

Spread / Lowest Target

-55.12%

Trading Rating

Investor Rating

ESG Refinitiv